{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:33:40Z","timestamp":1761514420678,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.yebeh.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T12:27:29Z","timestamp":1562675249000},"page":"14-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"PA","title":["Pharmacist impact on adherence of valproic acid therapy in pediatric patients with epilepsy using active education techniques"],"prefix":"10.1016","volume":"98","author":[{"given":"Mubai","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xurui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanghao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.06.003_bb0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eplepsyres.2013.02.002","article-title":"Prevalence of epilepsy in the People's Republic of China: a systematic review","volume":"105","author":"Gu","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25\u202fyears and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yebeh.2018.06.025","article-title":"Associated and predictive factors of quality of life in patients with temporal lobe epilepsy","volume":"86","author":"Chen","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1472-8206.2001.00055.x","article-title":"Clinical pharmacology and therapeutic use of the new antiepileptic drugs","volume":"15","author":"Perucca","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2019.06.003_bb0030","first-page":"S79","article-title":"Compliance during treatment of epilepsy","volume":"29","author":"Leppik","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0040","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality findings from the RANSOM Study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0045","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","article-title":"Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population","volume":"49","author":"Davis","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0050","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study","volume":"50","author":"Faught","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0055","first-page":"E55","article-title":"Contributions of pharmacists in the treatment of epilepsy: a systematic review","volume":"8","author":"Reis","year":"2016","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0060","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1592\/phco.26.10.1369","article-title":"Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy","volume":"26","author":"Bond","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0065","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2147\/PPA.S124028","article-title":"The impact of a pharmacist-led educational interview on medication adherence of Saudi patients with epilepsy","volume":"11","author":"AlAjmi","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2008.10.014","article-title":"Patients with epilepsy's perception on community pharmacist's current and potential role in their care","volume":"14","author":"McAuley","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"Aids"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1755-5949.2010.00225.x","article-title":"Description of study population and analysis of factors influencing adherence in the observational Italian study \u201cevaluation of pharmacotherapy adherence in bipolar disorder\u201d (EPHAR)","volume":"18","author":"Barraco","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0085","first-page":"690","article-title":"Validation on the simplified medication adherence questionnaire (SMAQ) in renal transplant patients on tacrolimus","volume":"31","author":"Ortega Suarez","year":"2011","journal-title":"Nefrologia"},{"author":"World Health Organization","key":"10.1016\/j.yebeh.2019.06.003_bb0090"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0095","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1590\/S0100-40422009000500027","article-title":"Determination of valproic acid in serum by high performance liquid chromatography with diode array detection (Hplc-Dad), after derivatization with phenacyl bromide","volume":"32","author":"Antunes","year":"2009","journal-title":"Quim Nova"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0100","first-page":"979","article-title":"Determination of valproic acid in human plasma using dispersive liquid\u2013liquid microextraction followed by gas chromatography-flame ionization detection","volume":"18","author":"Fazeli-Bakhtiyari","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0105","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J Hum Genet"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.eplepsyres.2017.02.015","article-title":"Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy","volume":"132","author":"Wang","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.seizure.2005.05.003","article-title":"Drug compliance of children and adolescents with epilepsy","volume":"14","author":"Asadi-Pooya","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0120","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/epi.12126","article-title":"Adherence to antiepileptic medicines in children: a multiple-methods assessment involving dried blood spot sampling","volume":"54","author":"Shah","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0125","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1528-1167.2010.02789.x","article-title":"Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy","volume":"52","author":"Modi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1528-1167.2008.01645.x","article-title":"Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions","volume":"49","author":"Paschal","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0135","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.13097","article-title":"Applying a perceptions and practicalities approach to understanding nonadherence to antiepileptic drugs","volume":"56","author":"Chapman","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.yebeh.2018.06.022","article-title":"Predictors of nonadherence in children and adolescents with epilepsy: a multimethod assessment approach","volume":"85","author":"Alsous","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jpeds.2011.05.018","article-title":"Electronic measurement of medication adherence in pediatric chronic illness: a review of measures","volume":"159","author":"Lngerski","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0155","doi-asserted-by":"crossref","first-page":"E961","DOI":"10.1542\/peds.2007-1690","article-title":"One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur","volume":"121","author":"Modi","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/pgmj.61.715.401","article-title":"Drug compliance and seizure control in epileptic children","volume":"61","author":"Lisk","year":"1985","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0165","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0170","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.0000000000002791","article-title":"Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study","volume":"87","author":"Gollwitzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0175","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/WNL.0000000000001023","article-title":"Antiepileptic drug nonadherence predicts pediatric epilepsy seizure outcomes","volume":"83","author":"Modi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/medicina54040060","article-title":"Association between adverse effects and parental beliefs about antiepileptic medicines","volume":"54","author":"Ili\u0107","year":"2018","journal-title":"Medicina"},{"issue":"5","key":"10.1016\/j.yebeh.2019.06.003_bb0185","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11096-013-9817-5","article-title":"The impact of pharmacist's couneling on pediatric patients' caregiver's knowledge on epilepsy and its treatment in a tertiary hospital","volume":"35","author":"Chen","year":"2013","journal-title":"Int J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0190","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-2125.1981.tb01316.x","article-title":"Serum phenytoin concentration and clinical response in patients with epilepsy","volume":"12","author":"Gannaway","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1528-1157.1988.tb04408.x","article-title":"If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study","volume":"29","author":"Woo","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.06.003_bb0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejps.2018.06.033","article-title":"Population pharmacokinetics of valproic acid in epileptic children: effects of clinical and genetic factors","volume":"122","author":"Xu","year":"2018","journal-title":"Eur J Pharm Sci"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:30:04Z","timestamp":1761503404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550501930188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"alternative-id":["S152550501930188X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.06.003","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacist impact on adherence of valproic acid therapy in pediatric patients with epilepsy using active education techniques","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}